Cost-Utility and Cost-Effectiveness of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

By Charmi Patel

June 20, 2024

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, leading to various debilitating symptoms. The economic burden of MS is significant, with Disease-modifying drugs (DMDs) constituting a major portion of healthcare costs. The cost-effectiveness and cost-utility of DMDs for relapsing-remitting multiple sclerosis (RRMS) is the focus of this systematic study.

Key Findings

First-Line Treatments: Studies reveal the cost-effectiveness of various DMDs such as dimethyl fumarate, natalizumab, ozanimod, interferon beta-1a, ocrelizumab, ofatumumab, and teriflunomide. These medications show incremental cost-effectiveness ratios (ICERs) ranging from $13,110/QALY to $48,000/QALY, offering improved outcomes and higher Quality-Adjusted Life Years (QALYs) for RRMS patients.

Second-Line Treatments: Noteworthy findings include the cost-effectiveness of ofatumumab and alemtuzumab, with ICERs of $24,189/QALY and $32,000/QALY, respectively. These treatments demonstrate superior outcomes and higher QALYs compared to other DMDs. Ocrelizumab emerges as a beneficial treatment option for RRMS patients, with an ICER of $166,338/QALY.

Third-Line Treatments: Studies on highly active RRMS (HDA) patients indicate the cost-effectiveness of cladribine tablets over alemtuzumab, fingolimod, and natalizumab, with ICERs ranging from $20,000/QALY to $40,000/QALY. Cladribine tablets are identified as a dominant and cost-effective treatment for HDA patients.

DMDs in Highly Active RRMS Patients: Natalizumab is highlighted as a cost-effective treatment choice for highly active RRMS patients, offering improved outcomes and higher QALYs with an ICER of $30,000/QALY compared to other DMDs.

DMDs in Secondary Progressive MS (SPMS): Siponimod is identified as a cost-effective treatment option for SPMS patients, providing greater QALYs and Years of Life (YLs) with an ICER of $25,000/QALY compared to other DMDs.

Rituximab Analysis: Studies on rituximab reveal lower costs and higher QALYs in MS patients compared to natalizumab, with an ICER of $35,000/QALY. Rituximab emerges as a promising treatment option for MS management.

Conclusion

The review points out how crucial it is to treat RRMS with DMDs that are both helpful and affordable. Cladribine tablets, natalizumab, alemtuzumab, and siponimod emerged as optimal choices for different subsets of MS patients. Oral DMDs were favoured over injectable and intravenous options due to their convenience and cost-effectiveness. Care-oriented strategies like Best Supportive Care (BSC) and Symptom Management (SM) were recommended over drug-focused approaches for RRMS treatment.

Recommendations

Healthcare policymakers, neurologists, and stakeholders should consider the local context and cost-effectiveness data when making decisions about MS treatment strategies. Further research is needed to explore the long-term effectiveness and cost implications of different DMDs across diverse healthcare settings.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.